Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimono, D.
Right arrow Articles by Koshiyama, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimono, D.
Right arrow Articles by Koshiyama, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 24:971, 2001
© 2001 by the American Diabetes Association, Inc.

Letters: Comments and Responses
Letter

Lack of Effect of Pioglitazone on Postprandial Triglyceride Levels in Type 2 Diabetes

Dai Shimono, MD, Naomitsu Kuwamura, MD, Yoshio Nakamura, MD and Hiroyuki Koshiyama, MD

Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo, Japan

We read with interest an article by Aronoff et al. (1), which indicated that monotherapy of pioglitazone, a peroxisome proliferator–activated receptor (PPAR)-{gamma} agonist, can improve lipid profile as well as glycemic control in type 2 diabetes. However, because they evaluated dyslipidemia in the fasted state, as most investigators do, it remains unknown whether pioglitazone may ameliorate postprandial dyslipidemia, which has recently been suggested to be an independent risk factor of atherosclerosis (456). We have previously indicated that troglitazone, another PPAR-{gamma} agonist, can cause a decrease in postprandial triglyceride levels in subjects with type 2 diabetes, although there is no significant relationship between a decrease in postprandial triglyceride levels and a decrease in intima-media thickness (IMT) of the common carotid artery (2,3).

In the present study, we investigated whether pioglitazone, another PPAR-{gamma} agonist, can decrease postprandial triglyceride in type 2 diabetes. Subjects included a total of 150 (87 men and 63 women, mean ± SEM age 61.1 ± 0.8 years) Japanese subjects with type 2 diabetes. HbA1c, total cholesterol, and postprandial triglycerides were measured 3 and 6 months after pioglitazone in the subjects receiving pioglitazone (30 mg/day) in combination with sulfonylurea drugs (n = 75) and in the control subjects, who were only receiving sulfonylurea drugs (n = 75). Postprandial triglyceride levels were examined 2 h after the conventional breakfast, as described previously (2). Although HbA1c showed a statistically significant decrease in comparison with control subjects (-0.885 ± 0.118 vs. 0.072 ± 0.130%, respectively, P < 0.05), there was no statistically significant change in total cholesterol (197.1 ± 4.7 vs. 202.7 ± 3.6 mg/dl, P = 0.350) or in postprandial triglycerides (150.3 ± 11.6 vs. 152.0 ± 12.4 mg/dl, P = 0.921).

Various PPAR target genes involved in fatty acid metabolism, such as lipoprotein lipase, have been identified to have PPAR response elements (7), which may, at least partly, result in an inhibitory effect of PPAR-{gamma} agonists on plasma triglyceride levels. This preliminary result, however, suggests that pioglitazone does not decrease postprandial dyslipidemia unlike troglitazone, suggesting a possibility that PPAR-{gamma} agonists may act differently on postprandial triglycerides. Taken together with our previous results, which showed that there is no relationship between a decrease in postprandial triglyceride and that in IMT after troglitazone (2,3), and with the fact that there is no correlation between postprandial triglyceride and IMT in a total of 250 subjects with type 2 diabetes (H. Koshiyama, unpublished data), it appears that postprandial triglyceride has no great impact on early atherosclerotic process, at least, in Japanese subjects with type 2 diabetes.

FOOTNOTES

Address correspondence to Hiroyuki Koshiyama, Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo 660-0828, Japan. E-mail: ime{at}amahosp.amagasaki.hyogo.jp.

References

  1. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 23:1605–1611, 2000[Abstract/Free Full Text]
  2. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818–1820, 1998[Abstract/Free Full Text]
  3. Koshiyama H, Tanaka S, Minamikawa J, Nakao K: Relationship between postprandial triglyceride level and intima-media thickness of carotid artery after troglitazone treatment in type 2 diabetes. In Lipoprotein Metabolism and Atherogenesis. Kita M, Yokode M, Eds. Tokyo, Springer, 2000, p. 154–156
  4. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR: Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 23:823–828, 1992[Abstract/Free Full Text]
  5. Uiterwaal CS, Grobbee DE, Witteman JC, van Stiphout WA, Krauss XH, Havekes LM, de Bruijn AM, van Tol A, Hofman A: Postprandial triglyceride response in young adult men and familial risk for atherosclerosis. Ann Intern Med 121:576–583, 1994[Abstract/Free Full Text]
  6. Grønholdt M-LM, Nordestgaard BG, Nielsen TG, Sillesen H: Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke 27:2166–2172, 1996[Abstract/Free Full Text]
  7. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev 20:649–688, 1999 [Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
D. S.H. Bell
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia: Response to Goldberg et al.
Diabetes Care, December 1, 2005; 28(12): 2983 - 2984.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. P.H. van Wijk, E. J.P. de Koning, M. Castro Cabezas, and T. J. Rabelink
Rosiglitazone Improves Postprandial Triglyceride and Free Fatty Acid Metabolism in Type 2 Diabetes
Diabetes Care, April 1, 2005; 28(4): 844 - 849.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimono, D.
Right arrow Articles by Koshiyama, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimono, D.
Right arrow Articles by Koshiyama, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum